Vera is developing Atacicept, a first and best-in-class antibody to treat IgA Nephropathy (IgAN), the third most common cause of kidney disease, as well as Lupus Nephris, a common problem for lupus patients. Vera expects data from its Phase 2b ORIGIN study in IgAN to be released in early 2023, and expects to start a Phase 3 in Lupus Nephritis in late 2022. Vera also licensed in an antibody against BK virus to improve kidney survival post transplant. Late stage studies for such should start by early 2023.